1. Academic Validation
  2. Peptidomimetic Vinyl Heterocyclic Inhibitors of Cruzain Effect Antitrypanosomal Activity

Peptidomimetic Vinyl Heterocyclic Inhibitors of Cruzain Effect Antitrypanosomal Activity

  • J Med Chem. 2020 Mar 26;63(6):3298-3316. doi: 10.1021/acs.jmedchem.9b02078.
Bala C Chenna 1 Linfeng Li 1 Drake M Mellott 1 Xiang Zhai 1 Jair L Siqueira-Neto 2 Claudia Calvet Alvarez 2 Jean A Bernatchez 2 Emily Desormeaux 1 Elizabeth Alvarez Hernandez 1 Jana Gomez 1 James H McKerrow 2 Jorge Cruz-Reyes 1 Thomas D Meek 1
Affiliations

Affiliations

  • 1 Department of Biochemistry & Biophysics, Texas A&M University, 301 Old Main Drive, College Station, Texas 77843, United States.
  • 2 Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California-San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.
Abstract

Cruzain, an essential cysteine protease of the parasitic protozoan, Trypanosoma cruzi, is an important drug target for Chagas disease. We describe here a new series of reversible but time-dependent inhibitors of cruzain, composed of a dipeptide scaffold appended to vinyl heterocycles meant to provide replacements for the irreversible reactive "warheads" of vinyl sulfone inactivators of cruzain. Peptidomimetic vinyl heterocyclic inhibitors (PVHIs) containing Cbz-Phe-Phe/homoPhe scaffolds with vinyl-2-pyrimidine, vinyl-2-pyridine, and vinyl-2-(N-methyl)-pyridine groups conferred reversible, time-dependent inhibition of cruzain (Ki* = 0.1-0.4 μM). These cruzain inhibitors exhibited moderate to excellent selectivity versus human cathepsins B, L, and S and showed no apparent toxicity to human cells but were effective in cell cultures of Trypanosoma brucei brucei (EC50 = 1-15 μM) and eliminated T. cruzi in infected murine cardiomyoblasts (EC50 = 5-8 μM). PVHIs represent a new class of cruzain inhibitors that could progress to viable candidate compounds to treat Chagas disease and human sleeping sickness.

Figures